Proven Results with ILARIS

ILARIS® is the first once-monthly injection that is FDA approved for Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) in children 2 years of age and older. This FDA approval was based on research that included 190 children.

100% of children with SJIA had no fever 3 days after taking their first dose of ILARIS

In a study, SJIA symptom improvements were seen after just one dose of ILARIS

3 days after taking their first dose of ILARIS, 100% of children with SJIA had no fever

Approximately 8 out of 10 children experienced improvements in their SJIA symptoms 15 days after their first dose of ILARIS

15 days after their first dose of ILARIS, approximately 8 out of 10 children experienced improvement in their SJIA symptoms (fever and painful and/or swollen joints)

ILARIS Can Help Reduce or Stop
Corticosteroid Use*

  • Almost half (46%, 42/92) of the children whose SJIA symptoms were controlled appropriately were able to stop taking corticosteroids completely

  • Of the children whose SJIA symptoms were controlled, nearly two-thirds (62%, 57/92) of those taking ILARIS were on a lower dose of corticosteroids

*128 patients entered the clinical study taking corticosteroids. 92 of these patients entered a part of the clinical trial (up to 5 months) to see if they could reduce or stop taking corticosteroids.

ILARIS can reduce or stop corticosteroid use
ILARIS can reduce or stop corticosteroid use

Talk to a doctor about whether ILARIS may be right for your child.

Next: Safety Considerations